Memantine Merz

Current Opinion in Investigational Drugs

Volumn 3, Issue 5, 2002, Pages 798-806

  Kilpatrick, Gavin J ^a   Tilbrook, Gary S ^a  

^a CeNeS Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DIZOCILPINE; DRUG; EBIXIA; LEVODOPA; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SUN Y 7017;

AIDS RELATED COMPLEX; ANALGESIC ACTIVITY; ANTIVIRAL ACTIVITY; BINDING COMPETITION; CLINICAL TRIAL; DEMENTIA; DOSE RESPONSE; DRUG BINDING SITE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; DYSKINESIA; GLAUCOMA; HUMAN; IC 50; MENTAL DISEASE; NEURALGIA; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; CLINICAL TRIALS; DEMENTIA; EXCITATORY AMINO ACID ANTAGONISTS; GLAUCOMA; HUMANS; MEMANTINE; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036591238     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. 88084 Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Bormann J Eur J Pharmacol 1989 166 3 591-592
2. 125847 Neuroprotective effect of memantine demonstrated in vivo and in vitro. Seif El Nasr M, Peruche B, Rossberg C, Mennel HD, Krieglstein J Eur J Pharmacol 1990 185 1 19-24
3. 127900 Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem brain study. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P Eur J Pharmacol 1991 206 4 297-300
4. 131388 gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: Prevention by memantine. Muller WE, Schroder HC, Ushijima H, Dapper J, Bormann J Eur J Pharmacol 1992 226 3 209-214
5. 203943 Effects of memantine and MK-801 on NMDA-induced currents in cultured neurons and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Frankiewicz T, Potier B, Bashir ZI, Collingridge GL, Parsons CG Br J Pharmacol 1996 117 4 689-697
6. 207602 Infusion of (+)-MK-801 and memantine - Contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Zajaczkowski W, Quack G, Danysz W Eur J Pharmacol 1996 296 3 239-246
7. 217369 Neurobiological Technologies, Inc begins human clinical trials of memantine. Neurobiological Technologies Inc Press Release 1996 August 26
8. 228879 Neurobiological Technologies Inc starts phase II memantine trial with NIH AIDS unit. Neurobiological Technologies Inc Press Release December 18 1996
9. 244173 Neurobiological Technologies Inc starts phase II memantine trial potential treatment for neuropathic pain. Neurobiological Technologies Inc Press Release April 29 1997
10. 275198 Allergan Speciality Therapeutics memantine phase III trials. FDC Repoorts Pink Sheet 1997 60 2 T&G:12
11. 275797 Allergan Reports 1997 Operating Results. Allergan Inc Press Release January 27 1998
12. 303274 Neurobiological Technologies Inc initiates phase IIb trial of Memantine for diabetic peripheral neuropathy. Potential oral analgesic for diabetics with pain and sleep disturbances. Neurobiological Technologies Inc Press Release November 02 1998
13. 304949 AIDS activist highlights need for AIDS Dementia treatments following Neurobiological Technologies Inc annual meeting. Neurobiological Technologies Inc Press Release 1998 November 12
14. 319530 Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: In vitro and in vivo characterization. Parsons CG, Danysz W, Bartmann A, Spielmanns P, Frankiewicz T, Hesselink M, Eilbacher B, Quack G Neuropharmacology 1999 38 1 85-108
15. 339622 Neurobiological Technologies Inc completes enrollment in phase IIB trial of memantine for diabetic peripheral neuropathy. Neurobiological Technologies Inc Press Release 1999 September 14
16. 356815 Neurobiological Technologies Inc announces positive results from phase III trial of Memantine for moderately severe to severe Alzheimer's disease. Neurobiological Technologies Inc Press Release February 22 2000
17. 357384 Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data. Parsons CG, Danysz W, Quack G Neuropharmacology 1999 38 6 735-767 Thorough review of available preclinical data on memantine.
18. 362282 New promising results for patients with vascular dementia. Merz & Co GmbH Press Release April 10 2000
19. 365215 Statistical significance given for Memantine trial results for diabetic neuropathic pain by Neurobiological Technologies Inc. Neurobiological Technologies Inc Press Release 2000 May 4
20. 365728 Annual Report 19999. Allergan Inc Annual Report December 31 1999
21. 372773 Forest Laboratories announces agreement with Merz & Co for license to memantine. Merz & Co GmBH Press Release Jun 29 2000
22. 372805 Neurobiological Technologies Inc discloses financial ramifications of US marketing agreement between Merz + Co and Forest Laboratories Inc for menamantine. Neurobiological Technologies Inc Press Release June 30 2000
23. 373491 Drug development pipeline: Memantine. Merz & Co GmBH Company Communication 2000 July 07
24. 373560 Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Kornhuber J, Quack G Neurosci Lett 1995 195 2 137-139
25. 376900 Memantine protects against neuronal degeneration induced by A-β (I-40) in the CAI subfield of the rat hippocampus. Alvarez XA, Miguel-Hidalgo J, Quack G, Cacabelos R Br J Clin Pharmacol 2000 July 15-20 Abs 687
26. 378845 H Lundbeck A/S licenses memantine for the treatment of Alzheimer's disease and enters into a strategic co-operation agreement with the German company. H Lundbeck A/S Press Release August 11 2000
27. 387456 Subtype selectivity of several amino-alkyl-cyclohexanes on NMDA receptors expressed in Xenopus oocytes. Spielmanns P, Parsons C, Ruppersberg JP, Plimkert P Abstr Soc Neurosci 2000 26 1 Abs 42.6
28. 388176 Neurobiological Technologies receives $2.5 million payment for memantine. Neurobiological Technologies Inc Press Release November 01 2000
29. 397370 Forest Laboratories announces product developments for memantine, alvameline and Tiazac. Forest Laboratories Inc Press Release January 30 2001
30. 407579 Annual report 2000 - Allergan Inc. Allergan Inc Annual Report April 01 2001
31. 407588 Neurobiological Technologies recives second payment of $2.25 million for memantine. Neurobiological Technologies Inc Press Release April 30 2001
32. 408525 Form 10K - Allergan Specialty Therapeutics Inc. Allergan Specialty Therapeutics Inc Annual Report February 28 2001
33. 417195 Suntory Pharmaceuticals: Products and R&D pipeline. Suntory Ltd Company World Wibe Wes Site July 30 2001
34. 417819 Neurobiological Technologies provides update on phase III trial - Memantine to be assessed in the treatment of diabetic neuropathy - Forest Laboratories conducting study. Neurobiological Technologies Inc Press Release August 02 2001
35. 418013 Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus - Identification of aminoadamantane derivatives bearing two pharmacophoric amine groups. Stamatiou G, Kolocouris A, Kolocouris N, Fytas G, Foscolos GB, Neyts J, De Clercq E Bioorg Med Chem Lett 2001 11 16 2137-2142
36. 418463 US Specialty Pharmaceuticals. Monthly dose. Merril Lynch Capital Markets 2001 July
37. 428021 Neurobiological Technologies summarizes data for memantine. Neurobiological Technologies Inc Press Release 2001 May 14
38. 428050 The adamantyl group in medicinal agents. 1. Hypoglycemic N-arylsulfonyl-N′-adamantylureas. Gerzon K, Krumkalns EV, Brindle RL, Marshall FJ, Root MA J Med Chem 1963 6 760-763
39. 428061 How to overcome resistance of influenza A viruses against adamantane derivatives. Scoltissek C, Quack G, Klenk HD, Webster RG, Antiviral Res 1998 37 2 83-95
40. 428064 Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W Neuropharmacology 1995 34 10 1239-1258
41. 18F-MEM): A potential radioligand for mapping the NMDA-receptor complex. Samnick S, Ametamey S, Leenders KL, Vontobel P, Quack G, Parsons CG, Neu H, Schubiger PA Nucl Med Biol 1998 25 4 323-330
42. 428067 Fluorine-18 radiolabeling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor. Ametamey SM, Samnick S, Leenders KL, Vontobel P, Quack G, ,Parsons CG, Schubiger PA J Recept Signal Transduct Res 1999 19 1-4 129-141
43. 428072 Different binding affinities of NMDA receptor channel blockers in various brain regions - Indication of NMDA receptor heterogeneity. Bresink I, Danysz W, Parsons CG, Mutschler E Neuropharmacology 1995 34 5 533-540
44. 428074 Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents - Preclinical studies. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G Neurosci Biobehav Rev 1997 21 4 455-468
45. 428076 Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Parsons CG, Gruner R, Rozental J, Millar J, Lodge D Neuropharmacology 1993 32 12 1337-1350
46. 428080 Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Bresink I, Benke TA, Collett VJ, Seal AJ, Parsons CG, Henley JM, Collingridge GL Br J Pharmacol 1996 119 2 195-204
47. 428091 Memantine prevents quinolinic acid-induced hippocampal damage. Keilhoff G, Wolf G Eur J Pharmacol 1992 219 3 451-454
48. 428094 Learning deficits induced by chronic intraventricular infusion of quinolinic acid - Protection by MK-801 and memantine. Misztal M, Frankiewicz T, Parsons CG, Danysz W Eur J Pharmacol 1996 296 1 1-8
49. 428096 Potential therapies for a novel animal model of Alzheimer's disease-chronic neuroinflammation of transgenic rats that overexpress human β-amyloid. Wenk GL, Hauss-Wegrrzyniak W, Baker LM, Danysz W Neurobiol Aging 1998 19 S129
50. 428103 Memantine enhances ischemic tolerance. Parsons CG, Frankiewicz T, Lazarewicz JW, Gadamski R Ann Meet Am Acad Neurol 2001 P05.065
51. 428113 Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1. Giulian D, Vaca K, Noonan CA Science 1990 250 4987 1593-1596
52. 428114 Activity-dependent neuronal plasticity following tissue injury and inflammation. Dubner R, Ruda MA Trends Neurosci 1992 15 3 96-103
53. 428115 The clinically tested N-methyl-D-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy. Eisenberg E, LaCross S, Strassman AM Neurosci Lett 1995 187 1 17-20
54. 428117 Behavioral and electrophysiological effects of memantine in a primate model of peripheral neuropathy. Carlton SM, Rees H, Gondesen K, Tsuruoka M, Willis WD Soc Neurosci Abs 1994 20 Abs 18
55. 428118 Elevated glutamate levels in the viteous body of humans and monkeys with glaucoma. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA Arch Ophthalmol 1996 114 3 299-305
56. 428119 Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Lagreze WA, Knorle R, Bach M, Feuerstein TJ Invest Ophthalmol Vis Sci 1998 39 6 1063-1066
57. 428120 Efficacy and safety of memantine, and NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey. Hare W, Wolde Mussie E, Lai R, Ton H, Ruiz G, Feldmann B, Wijono M, Chun T, Wheeler L Surv Ophthalmol 2001 45 Suppl 3 S284-S289. Preclinical data supporting the hypothesis that memantine will be effective in glaucoma.
58. 428122 Pharmacodynamics and pharmacokinetics of memantine. Wesemann W, Sontag KH, Maj J Arzneimittelforschung 1983 33 8 1122-1134
59. 428123 Memantine-induced dopamine release in the prefrontral cortex and striatum of the rat - A pharmacokinetic microdialysis study. Spanagel R, Eilbacher B, Wilke R Eur J Pharmacol 1994 262 1-2 21-26
60. 428124 Distribution of metabolism of the potential anti-parkinson drug memantine in the human. Wesemann W, Sturm G, Funfgeld EW J Neural Transm Suppl 1980 16 143-148
61. 428126 Memantine induces heat shock protein HSP70 in the posterior cingulate cortex, retrosplenial cortex and dentate gyrus of rat brain. Tomitaka S, Hashimoto K, Narita N, Sakamoto A, Minabe Y, Tamura A Brain Res 1996 740 1-2 1-5
62. 428127 Comparison of glutamate antagonists in continuous multiple-trial and singlee-trial dark avoidance. Misztal M, Danysz W Behav Pharmacol 1995 6 550-561
63. 428128 Effects of intravenous administration of memantine in Parkinsonian patients. Fischer PA, Jacobi P, Schneider E, Schonberger B Arzneimittelforschung 1977 27 7 1487-1489
64. 428129 Memantine in the treatment of senile dementia of the Alzheimer type. Fleischhacker WW, Buchgeher A, Schubert H Prog Neuropsychopharmacol Biol Psychiatry 1986 10 1 87-93
65. 428131 Influence of urine PH and urinary flow on the renal excretion of memantine. Fruedenthaler S, Meineke I, Schreeb KH, Boakye E, Gundert-Remy Gleiter CH Br J Clin Pharmacol 1998 46 6 541-546
66. 428132 Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. Rabey JM, Nissipeanu P, Korczyn AD J Neural Transm Park Dis Dement Sect 1992 4 277-282
67. 428133 Effects of oral memantine administration on Parkinson symptoms. Results of a placebo-controlled multicenter study. Schneider E, Fischer PA, Clemens R, Balzereit F, Funtgeld EW, Haase HJ Dtsch Med Wochenschr 1984 109 25 987-990
68. 428134 Effect of memantine (NMDA antagonist) on Parkinson's disease: A double-blind crossover, randomized study. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R Clin Neuropharmacol 1999 22 5 273-276
69. 428135 Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Ditzler K Arzneimittelforschung 1991 41 8 773-780
70. 428137 Memantine in the treatment of mild-to-moderate dementia syndrome. A double-blind, placebo-controlled study. Gortelmeyer R, Erbler H Arzneimittelforschung 1992 42 7 904-913
71. 428138 Memantine in severe dementia: Results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Winblad B, Poritis N Int J Geriatr Psychiatry 1999 14 2 135-146
72. 428157 Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: A randomized, double-blind, cross-over study. Nikolajsen L, Gottrup H, Kristensen AG, Jensen TS Anesth Analg 2000 91 4 960-966
73. 428161 Memantine in moderately severe to severe Alzheimer's disease (AD): Results of a placebo-controlled 6-month trial. Reisberg B Neurobiol Aging 2000 21 S275 Details of a US phase III study in Alzheimer's disease.
74. 428165 Pharmacotoxic psychosis after memantine in Parkinson's disease. Riederer P, Lange KW, Kornhuber J, Danielczyk W Lancet 1991 338 8773 1022-1023
75. 428282 Treatment of dementia with memantine. Goertelemeyer R, Pantev M, Parsons CG, Quack G Spektrum Der Neurorehabilitation (Ed: Von Wild K) 1993 50-56
76. 428284 Clinical and behavioural evaluation in long-term care patients with mild-to-moderate dementia under memantine treatment. Pantev M, Ritter R, Goertelmeyer R Zeitschrift Fur Gerontopsychologie Und Psychiatrie 1993 6 103-117
77. 429181 Merrill Lynch & Co: US Specialty Pharmaceuticals - Monthly Dose; October 2001. Gilbert GB, Mahajan A Analyst Report 2001 October
78. 435878 Product pipeline: Memantine. H Lundbeck A/S Company Communication January 15 2002
79. 440770 Memantine - Ebixa - Approved for treatment of Alzheimer's disease. H Lundbeck A/S Press Release 2002 February 20